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Background. Cannabis use has been reported to be associated with an earlier onset of symptoms in 
patients with first-episode psychosis, and a worse outcome in those who continue to take cannabis. 
In general, studies have concentrated on symptoms of psychosis rather than mania. In this study, 
using a longitudinal design in a large naturalistic cohort of patients with first-episode psychosis, we 
investigated the relationship between cannabis use, age of presentation to services, daily 
functioning, and positive, negative and manic symptoms. 
Method. Clinical data on 502 patients with first-episode psychosis was collected using the MiData 
audit database from 7 London-based Early Intervention in psychosis teams. Individuals were 
assessed at 2 time points – at entry to the service and after 1 year. On each occasion, Positive and 
Negative Syndrome Scale, Young Mania Rating Scale, and Global Assessment of Functioning scale 
disability subscale were rated. At both time-points, the use of cannabis and other drugs of abuse in 
the 6 months preceding each assessment was recorded. 
Results. Level of cannabis use was associated with a younger age at presentation, and manic 
symptoms and conceptual disorganisation, but not with delusions, hallucinations, negative 
symptoms or daily functioning. Cannabis users who reduced or stopped their use following contact 
with services had the greatest improvement in symptoms at 1 year compared to continued users and 
non-users. Continued users remained more symptomatic than non-users at follow-up. 
Conclusions. Effective interventions for reducing cannabis use may yield significant health benefits 
for patients with first-episode psychosis. 
 
 
 
Key words: Cannabis, Schizophrenia, Bipolar Affective Disorder, Mania, Psychosis 
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Introduction 
There is growing evidence that cannabis use may increase the risk of developing schizophrenia 
(Manrique-Garcia et al 2012, Murray et al 2007), and that individuals with first-episode psychosis 
with a history of cannabis use have an earlier onset of psychotic symptoms and younger age at 
presentation to services (Gonzalez-Pinto et al 2011, Large et al 2011). Cannabis use has generally 
been reported to be associated with increased positive symptoms and increase in risk of relapse in 
patients with schizophrenia, with functional and symptomatic improvements reported to occur on 
discontinuation (Faber et al 2012, Foti et al 2010, Grech et al 2005, Kuepper et al 2011, Zammit et 
al 2008). Cannabis use has also been shown to affect mood (Henquet et al 2006), being reported to 
be associated with depressive symptoms and worse outcome in individuals with bipolar affective 
disorder (Strakowski et al 2007, van Rossum et al 2009). To our knowledge, no longitudinal studies 
have yet examined the relationship of cannabis use to symptoms of mania in patients with first-
episode psychosis. 
 
In this study, we examined the temporal relationship of cannabis use to manic and psychotic 
symptoms and to age at presentation to services in a large UK-based cohort of patients with first-
episode psychosis. We hypothesized that cannabis use would be associated with a younger age of 
presentation to services, and that cannabis use would be associated with a greater level of manic and 
psychotic symptoms and with poorer daily functioning. We also hypothesized that reducing or 
stopping cannabis use following the first psychotic episode would be associated with better 
symptomatic and functional improvement. 
 
Method 
Ethical approval for this study was obtained from Wandsworth Research Ethics Committee. The 
study was conducted in accordance with the ethical standards laid down in the Declaration of 
Helsinki (1964, 2000). Clinical data were collected using the MiData audit database from 7 
London-based Early Intervention in psychosis (EI) teams, covering the London boroughs of Brent, 
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Camden, City and Hackney, Islington, Kensington and Chelsea, Lewisham, Southwark, 
Wandsworth, and Westminster (Fisher et al 2008, Ghali et al 2012). Within each team, clinicians 
(doctors and care-coordinators) completed training by HLF over a 4 1/2 hour session, including 
vignettes, practice sessions, and discussion of standardised ratings, and were required to 
demonstrate high reliability with expert raters (Fisher et al 2008). In keeping with standard practice 
in UK for first-episode psychosis teams, patient inclusion was based on a history of psychotic 
symptoms that lasted for more than 7 days. Individuals who only experienced psychotic symptoms 
during acute drug intoxication were not included in the study, but otherwise no prior assumptions 
were made about the cause or diagnosis of the psychotic illness. Individuals were assessed at 2 time 
points – at entry to the service and after 1 year in contact with the service. On each occasion, 
Positive and Negative Syndrome Scale (PANSS) (Kay et al 1987), Young Mania Rating Scale 
(YMRS) (Young et al 1978), and Global Assessment of Functioning scale disability subscale (GAF-
d) (Endicott et al 1976), were rated. At both time-points, the use of cannabis and other drugs of 
abuse in the 6 months preceding each assessment was recorded using the combined Alcohol and 
Drug Use scales (Drake et al 1996). Each drug was rated by clinicians on an operationalized 4-point 
scale (No Use, Use, Abuse, Dependence), as previously described (Drake et al 1996). On this scale, 
Use is defined as substance use with no evidence of persistent or recurrent social, occupational, 
psychological or physical problems related to use, and no evidence of recurrent dangerous use. 
Abuse is defined as substance use with the presence of any of these features. Dependence is defined 
as the criteria for Abuse, plus at least 3 of the following 7 items: 1) Much time is spent obtaining or 
using the substance; 2) Frequent intoxication or withdrawal interferes with other activities; 3) 
Important activities are given up because of substance use; 4) Continued use despite knowledge of 
substance-related problems; 5) Marked tolerance; 6) Characteristic withdrawal symptoms; 7) The 
substance is used to relieve or avoid withdrawal problems. At the second time point, clinical 
diagnosis and compliance with medication (where known) was also recorded. 
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Statistical analyses were completed using R version 2.14.1 (Ihaka and Gentleman 1996). We 
generated a linear model with age at presentation to services as the dependent variable, and level of 
cannabis use, alcohol use, nicotine use, cocaine use, and stimulant use in the preceding 6 months, 
gender, ethnicity, social functioning (GAF-d) and symptoms at presentation (PANSS total and 
YMRS) as independent variables. We then generated four separate linear models with baseline 
YMRS, PANSS positive (PANSS-P), PANSS negative (PANSS-N) and GAF-d scores as dependent 
variables and level of cannabis use, alcohol use, nicotine use, cocaine use, and stimulant use in the 
preceding 6 months, age at presentation, gender and ethnicity as independent variables. In each 
case, models were simplified using an Akaieke information criterion (AIC)-based stepwise method 
implemented in R (Ihaka and Gentleman 1996). Where cannabis was significantly related to the 
dependent variable in each ANOVA, we performed post-hoc Pearson's correlations on the level of 
cannabis use vs. the dependent variable, uncorrected for independent variables. 
 
In the follow-up sample, we compared baseline demographics and clinical measures with the full 
(baseline only) sample using student's t-test and chi squared test, where appropriate. We used four 
repeated measures ANOVAs to compare YMRS, PANSS (positive and negative) and GAF-d ratings 
at baseline and follow-up in 3 groups based on their change in cannabis use over the period of study 
– 1) patients who reported no cannabis use both at presentation and 1 year follow-up (“abstinent”), 
2) patients who reported a reduction or a discontinuation of their use of cannabis (“reduced”), 3) 
patients who reported a continuation or increase in their use of cannabis (“continued”). For all 
analyses, histogram and qq plots of residuals were used to confirm normality of data and two-tailed 
p values were employed to determine statistical significance. 
 
 
 
Results 
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Baseline data on recent cannabis, cocaine, stimulant and alcohol use was available in 502 first-
episode patients (320 male, 182 female). Demographic and clinical details are summarized in Table 
1. Age at presentation was predicted by a model driven primarily by level of cannabis use in the 
preceding 6 months (associated with a younger age of presentation; post-hoc, uncorrected r = 0.18; 
n = 502; p = 5 x 10-5) but also including level of alcohol use (associated with an older age at 
presentation) and ethnicity (see Table 2). PANSS-P scores were predicted by a model primarily 
driven by level of cannabis use (post-hoc, uncorrected r = 0.16; n = 502; p = 0.0004), but also 
including nicotine use, age and gender (Table 3). YMRS scores were predicted by a model that 
simplified to include level of cannabis use only (F(1,500) = 16.67; r = 0.18; n = 502; p = 5.2 x 10-5). 
PANSS-N scores were predicted by a model including alcohol use and gender (Table 4). GAF-d 
scores were predicted by a model including nicotine use and gender (Table 5). 
 
Post-hoc analyses of individual PANSS-P and YMRS components revealed that level of cannabis 
use was associated at presentation with increased conceptual disorganisation, excitement and 
hostility on PANSS-P; and with elevated mood and increased motor activity, sexual interest, 
irritability, speech – rate and amount, language – thought disorder, and disruptive – aggressive 
behaviour on YMRS (all p values < 0.005; n = 502). Of note, cannabis use at presentation was not 
associated with a significantly greater severity of hallucinations (p = 0.47) or delusions (p = 0.25). 
 
At one year follow-up, data on cannabis use in 271 first-episode patients was available (54% of 
baseline sample). Of these, 143 (53%) were non-users of cannabis both at baseline and at follow-up 
(“abstinent” group), 80 (30%) were cannabis users at baseline but had stopped at follow-up 
(“reduced” group), and 48 (17%) had either continued or increased their level of cannabis use from 
baseline to follow-up (“continued” group). Out of the 271 first-episode patients with follow-up data, 
221 (81%) had a diagnosis of schizophrenia or schizophreniform psychosis, 27 (10%) had a 
diagnosis of bipolar affective disorder, 13 (5%) had a diagnosis of depressive psychosis, and in 10 
(4%), the diagnosis was not recorded. Of those with a final diagnosis of bipolar affective disorder, 9 
(34%), and 7 (26%) were classified as being cannabis abusers and cannabis users, respectively, at 
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baseline. In terms of medication concordance, 163 (60%) patients were recorded as being compliant 
with medication, 19 (7%) as non-compliant, and in 89 (33%) patients, this information was not 
available. The sample with baseline and follow-up data did not differ from the full (baseline-only) 
sample in terms of age (t = 0.91, p = 0.36), gender (chisq = 1.16, p = 0.28), ethnicity (chisq = 3.415, 
p = 0.64), PANSS-P (mean[SD] = 19.1[7.7]; t = 1.55, p = 0.121), PANSS-N (mean[SD] = 
17.27[8.6], t = 1.01, p = 0.31), YMRS (mean[SD] = 10.8[9.6], t = 0.64, p = 0.52), GAF-d 
(mean[SD] = 48.9, t = 1.86, p = 0.62), or cannabis use (t = 1.07, p = 0.28), at presentation. 
 
ANOVA revealed a significant within-subjects effect of time for PANSS-P (F(1,268) = 163; n = 
271; p < 0.0001), PANSS-N (F(1,268) = 63.6; n = 271; p < 0.0001), YMRS (F(1,268) = 87.3; n = 
271 p < 0.0001) and GAF-d (F(1,268) = 136; n = 271 p<0.0001) with an improvement in all rating 
scales between baseline and follow-up (mean[SD] PANSS-P = 12.2[6.4]; PANSS-N = 12.9[7.2]; 
YMRS = 4.7[6.9]; GAF-d = 64.0[17.6]; n = 271). There was a significant interaction between 
change in cannabis use (“abstinent”, “reduced”, “continued”) and time for PANSS-P (F(2,268) = 
9.93; n = 271; p < 0.0001; Figure 1), YMRS (F(2,268) = 9.39; n = 271 p = 0.0001; Figure 2),  and 
GAF-d (F(2,268) = 6.24; n = 271; p = 0.002; Figure 3). There was no significant interaction 
between change in cannabis use and time for PANSS-N (F(2,268) = 2.65, p = 0.07). Compared to 
individuals in the “continued” group for cannabis use, those in the “abstinent” and “reduced” 
groups had lower PANSS-P (t = 3.26, 3.77; p = 0.001, 0.0003), YMRS (t = 2.4 3.57; p = 0.02, 
0.0007) and GAF-d scores (t = 3.0, 3.66; p = 0.004, 0.0004) at follow-up. Medication concordance 
was not found to differ with different patterns of cannabis use (90% concordance reported in the 
“abstinent” group, 90% in the “reduced” group and 86% in the “continued” group, n = 102, 50, 30 
respectively; Chisq = 0.32, p = 0.85). 
 
Discussion 
In keeping with previous studies, these data suggest cannabis use is associated with a younger age 
of presentation to services (Gonzalez-Pinto et al 2011, Large et al 2011), and that discontinuation or 
reduction of cannabis use is associated with enhanced symptomatic improvement in patients with 
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first-episode psychosis (Faber et al 2012, Foti et al 2010, Grech et al 2005, Kuepper et al 2011, 
Zammit et al 2008). 
 
In contrast, several recent studies of cannabis use in schizophrenia suggest that change in cannabis 
use may not affect symptomatology to such a great extent. Three studies failed to demonstrate any 
change in PANSS positive scores with reduction or discontinuation of cannabis, although in all of 
these studies, discontinuation was associated with improvement in social functioning 
(Barrowclough et al 2011, Faber et al 2012, Gonzalez-Pinto et al 2011). Another study found that, 
although there was no difference in clinical measures between cannabis users and non-users, 
cannabis users had more frequent hospital admissions (van Dijk et al 2012). A further group 
reported that individuals who continued to take cannabis were more likely to be compliant with 
medication, but, after correcting for this, cannabis users had higher levels of psychopathology 
compared to those who discontinued cannabis (Faridi et al 2012). Thus, although positive 
symptoms, as rated by PANSS, are not always associated with cannabis use in patients with 
schizophrenia and first-episode psychosis, all studies have reported an improvement in functioning 
with reduction in use. It is also clear that cannabis use may have a complex inter-relationship with 
medication concordance in some patients, although this did not appear to be an issue in the present 
study. It is interesting to note, although we found that cannabis did have an effect on PANSS 
positive scores in the present study, that this effect was primarily driven by aggression and 
disinhibition, rather than the more usually associated symptoms of delusions and hallucinations. It 
is possible that the effects of cannabis reduction on illness outcome may be most marked in patients 
with first-spisode psychosis. A recent meta-analysis found that reducing substance intake led to 
improvements in symptomatology, but that this effect was only present in patients with first-episode 
psychosis. In patients with more established illness, improvements were not statistically significant 
(Mullin et al 2012).  
 
Although other studies have found that cannabis use is associated with increases in positive affect 
(self-rated reports of happiness, cheerfulness, relaxation, enthusiasm and satisfaction) in the general 
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population (Henquet et al 2006), and that it can worsen outcome in bipolar disorder (Strakowski et 
al 2007, van Rossum et al 2009), our study is the first report, to our knowledge, of cannabis use 
being associated more closely with manic-type symptoms than with hallucinations and delusions in 
patients with first-episode psychosis. 
 
Our finding of an association between cannabis use and a younger age of presentation to services is 
in keeping with current evidence that cannabis use may lead to an earlier onset of psychotic 
symptoms (Large et al 2011). It is possible that individuals with earlier and more severe symptoms 
may be drawn to take cannabis for other reasons, or that younger individuals may simply be more 
likely to have taken cannabis in the preceding 6 months due to cannabis use being more prevalent in 
a younger age group. However, a recent meta-analysis concluded that these possibilities could not 
fully explain the association between cannabis use and earlier onset of psychosis (Large et al 2011). 
It should be noted that the 6 months prior to contact with services may have coincided with the 
onset of prodromal symptoms, and we cannot exclude the possibility that cannabis was used in an 
attempt to self-medicate.  
 
It is interesting to note that, in the present study, the level of PANSS-P scores at baseline were 
associated with nicotine use (at trend level) and with age, and that lower GAFd scores at baseline 
were also associated with nicotine use. Previous studies have reported an association between 
nicotine use and a greater severity of positive symptoms, as well as lower social functioning, in 
patients with first-episode psychosis and schizophrenia (Krishnadas et al 2012, Zhang et al 2012). 
Although the reasons for these associations have not been ascertained, it is possible that nicotine use 
may worsen symptoms and levels of disability, or may be used as self-medication in an effort to 
improve some aspects of functioning in the most unwell patients (Krishnadas et al 2012, Zhang et 
al 2012). The reason for our finding of an association between age and symptoms in this study is 
not known, but it is possible to speculate that older individuals were more likely to have been living 
away from home, with less daily contact from family members, and so their illness may have 
become more severe before being recognised. 
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We also found an association between alcohol use and less severe negative symptoms and between 
male gender and more severe negative symptoms. The finding of an association (albeit weak) 
between alcohol use and less severe PANSS-negative scores, has not been previously reported, to 
our knowledge, and may simply reflect the fact that individuals with lower negative symptoms are 
more capable of getting access to alcohol. The finding that male gender was associated with 
PANSS-negative scores has been established for many years (Abel et al 2010, Andreasen 1982). 
 
There are limitations to this study – most notably that cannabis and other drug use data were 
dependent on patient recall and disclosure – the alcohol and drug use scales are self-report scales.  
Furthermore, the data were recorded by a variety of different psychiatric team members who were 
not blind to treatment status, though all had received the same training. Only 27 patients were 
diagnosed with bipolar affective disorder at follow-up; therefore, manic-type symptoms, although 
associated with cannabis use, were unlikely to have been the primary presenting complaint in the 
majority of cases. Data on cannabis use at follow-up was not available in approximately 46% of the 
original sample. This was because follow-up assessments were abbreviated in some instances, with 
recordings of substance use being omitted, due to time pressures on the clinical teams involved in 
the study. Although the baseline demographics and clinical measures in patients with substance use 
data at both time points did not differ significantly from those with data from the first time point 
only, it is possible that the longitudinal analysis may not be fully representative of the total study 
population. 
 
Despite these limitations, the findings from this study are derived from a relatively large naturalistic 
cohort with a good coverage of different London teams and regions and so should be generalisable 
to other inner city services in the UK. This study suggests that efforts to identify effective 
interventions for reducing cannabis use are likely to yield significant health benefits for patients 
with first-episode psychosis.  
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Table 1: Demographic and baseline clinical details of EIS psychosis patients. 
 
Demographic or clinical variable N (%) or M (SD) 
Age 23.7 (4.9) 
Gender (M/F) 320 (64) /182 (36) 
Ethnicity (Caucasian/ Mixed/ Asian/ AC/ 
Chinese/ Other) 
170 (34)/ 43 (9)/ 71 (14)/ 192 (38)/ 24 (5)/ 2 (0) 
Education level (no qualifications/ GCSE/ A-
Level/ HND or professional qualification/ 
university but did not complete/ degree/ 
postgraduate/ other) 
107 (21)/ 145 (29)/ 59 (12)/ 22 (4)/ 74 (15)/ 49 
(10)/ 9 (2)/ 37 (7) 
Employment status (unemployed/ student/ part-
time/ full-time/ other) 
287 (57)/ 104 (21)/ 37 (7)/ 44 (9)/ 30 (6) 
Cannabis use (no use/ use/ abuse/ dependence) 295 (59)/ 95 (19)/ 94 (19)/ 18 (4) 
Alcohol use (no use/ use/ abuse/ dependence) 201 (40)/ 252 (50)/ 46 (9)/ 3 (1) 
Nicotine use (no use/ use/ abuse/ dependence) 279 (56)/ 164 (33)/ 13 (3)/ 46 (9) 
Cocaine use (no use/ use/ abuse/ dependence) 449 (89)/ 39 (8)/ 10 (2)/ 4 (1) 
Stimulant use (no use/ use/ abuse/ dependence) 477 (95)/ 19 (4)/ 5 (1)/ 1 (0) 
PANSS total 72.0 (24.6) 
PANSS positive  18.2 (7.8) 
PANSS negative  16.6 (8.3) 
YMRS  10.3 (10.1) 
GAF-D  51.3 (17.7) 
 
AC – Black African and African-Caribbean, GCSE – General Certificate of Secondary Education. A-level: Advanced-
Level General Certificate of Education. HND – Higher National Diploma. PANSS – Positive and Negative Syndrome 
Scale. YMRS – Young Mania Rating Scale. GAF-d – Global Assessment of Functioning scale – disability subscale, SD, 
standard deviation. 
13 
  
Table 2: Components of general linear model predicting age at presentation. 
 
 Estimate Std. Error t value p 
(Intercept) 25.5 3.33 7.66 9.5 x  10-14 
Cannabis use -1.18    0.26 -4.55 6.8 x  10-6 
Alcohol use 1.13 0.37 3.06 0.002 
Ethnicity (Caucasian) -1.89 3.35 -0.57 0.57 
Ethnicity (Mixed) -3.28 3.40 -0.96 0.34 
Ethnicity (Asian) -0.11 3.37 -0.032 0.97 
Ethnicity (AC) -2.17 3.34 -0.65 0.52 
Ethnicity (Chinese) -1.10 3.46 -0.32 0.75 
F(7,494) = 5.69; p = 2.4 x 10-06. AC -  Black African and African-Caribbean. 
 
Table 3: Components of general linear model predicting PANSS-positive scores at 
presentation.  
 
 Estimate Standard Error t value p 
(Intercept) 12.6 1.87 6.74 4.5 x  10-11 
Cannabis use 1.12 0.43 2.61 0.0094 
Nicotine use 0.73 0.41 1.76 0.079 
Age 0.16 0.07 2.16 0.032 
Gender (Male) 1.03 0.73 1.41 0.16 
F(3,498) = 5.76; p = 0.0002. PANSS – Positive and Negative Syndrome Scale. 
 
Table 4: Components of general linear model predicting PANSS-negative scores at 
presentation. 
 
 Estimate Standard Error t value p 
(Intercept) 16.62 0.70 23.75 2 x  10-16 
Alcohol use -1.30 0.56 -2.48 0.013 
Gender (Male) 1.55 0.77 2.02 0.044 
F(2,499) = 4.634;  p = 0.01. PANSS – Positive and Negative Syndrome Scale. 
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Table 5: Components of general linear model predicting GAF-d scores at presentation     
F(2,499) = 3.954;  p = 0.01. GAF-d – Global Assessment of Functioning scale – disability subscale 
 
 
 Estimate Standard Error t value p 
(Intercept) 54.2 1.37 39.69 2 x  10-16 
Nicotine use -1.74 0.87 -2.00 0.046 
Gender (Male) -2.74 1.65 -1.66 0.097 
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Figure 1: Interaction plot of the positive subscale of the Positive and Negative Syndrome Scale 
(PANSS-P) over time. Figure shows PANSS-P in patients with first-episode psychosis who 
reported no cannabis use both at presentation and 1 year follow-up (Abstinent), who reported a 
reduction or a discontinuation of their use of cannabis (Reduced), and who reported a continuation 
or increase in their use of cannabis between baseline and follow-up (Continued). Error bars show 
Standard Error of Mean. 
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Figure 2: Interaction plot of Young Mania Rating Scale (YMRS) over time. Figure shows 
YMRS in patients with first-episode psychosis who reported no cannabis use both at presentation 
and 1 year follow-up (Abstinent), who reported a reduction or a discontinuation of their use of 
cannabis (Reduced), and who reported a continuation or increase in their use of cannabis between 
baseline and follow-up (Continued). Error bars show Standard Error of Mean. 
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Figure 3: Interaction plot of the Global Assessment of Functioning scale - disability subscale 
(GAF-d) over time. Figure shows GAF-d in patients with first-episode psychosis who reported no 
cannabis use both at presentation and 1 year follow-up (Abstinent), who reported a reduction or a 
discontinuation of their use of cannabis (Reduced), and who reported a continuation or increase in 
their use of cannabis between baseline and follow-up (Continued). Error bars show Standard Error 
of Mean. 
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